Development of ligand-targeted liposomes for cancer therapy

Area of Science:

• Biotechnology
• Nanomedicine
• Oncology

Background:

• Targeted liposomal therapeutics offer improved antitumour efficacy and reduced toxicity.
• Ligand selection is crucial for reducing immunogenicity, extending circulation, and ensuring tumour targeting and drug release.

Purpose of the Study:

• To review advancements in targeted liposome technology for cancer therapy.
• To discuss strategies for liposome targeting in solid tumours and vascular applications.
• To highlight the potential of ligand-targeted liposomes as a superior therapeutic approach.

Main Methods:

• Review of ligand selection criteria for targeted liposomes.
• Discussion of novel assembly techniques, including micellar insertion technology.
• Analysis of targeting strategies for solid tumours and vascular targets.

Main Results:

• Ligand-targeted liposomes demonstrate significant antitumour efficacy with favorable toxicity profiles.
• Advanced assembly methods facilitate the clinical translation of targeted liposome technology.
• Anti-HER2 immunoliposomal doxorubicin is progressing to Phase I clinical trials.

Conclusions:

• Ligand-targeted liposomes represent an advanced and advantageous therapeutic strategy.
• Ongoing clinical trials are expected to provide further insights into the potential of these therapies.
• The development of targeted liposomes is poised to significantly impact cancer treatment.